CUSHINGS SYNDROME MARKET ANALYSIS

Market News

 Key Development

• In November 2019, osilodrostat, which is used for the treatment of patient with Cushing syndrome in adults, had got positive opinion by The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).Furthermore, on 6th March 2020, Isturisa (osilodrostat), has been approved by U.S Food and Drug Administration 9FDA). Isturisa (osilodrostat) is an oral tablet used in the patient who cannot go for pituitary gland surgery or has not been curative.
• In September 2019, positive result from the phase 3 clinical trial for RECORLEV (levoketoconazole) drug had been announced by Strongbridge Biopharma plc Company. RECORLEV (levoketoconazole) drug is used for the treatment of endogenous Cushing’s syndrome.
• In June 2018, pasireotide drug (Signifor, Novartis), which is used for the treatment of patient with Cushing syndrome who cannot go for pituitary gland surgery or has not been curative., had been approved by U.S Food and Drug Administration (FDA).